Showing results (1-10 of 408) with videos related to
Sort By:
Pageof 41
Hematology/Oncology Clinics of North America|April 28, 2020
Tagraxofusp for Blastic Plasmacytoid Dendritic Cell NeoplasmDanielle Hammond, Naveen PemmarajuLeukemia & Lymphoma|May 21, 2024
VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic): clinical review in a rapidly emerging fieldLuan Phan, Danielle Hammond, Nathaniel R Wilson, et al.Hematology. American Society of Hematology. Education Program|December 7, 2024
BPDCN: state of the artNaveen PemmarajuActa Haematologica|September 18, 2014
Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literatureNaveen Pemmaraju, Jorge CortesBlood Advances|August 26, 2020
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasmNaveen Pemmaraju, Marina KonoplevaClinical Advances in Hematology & Oncology : H&O|May 5, 2023
Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023Naveen Pemmaraju, Hagop KantarjianHematology. American Society of Hematology. Education Program|December 6, 2015
Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)Naveen Pemmaraju, Ruben MesaAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and ManagementNaveen Pemmaraju, Alison R MoliternoJournal of Hospital Medicine|April 29, 2008
Solifenacin-induced small bowel pseudo-obstructionNaveen Pemmaraju, Leonard S FeldmanExpert Opinion on Pharmacotherapy|January 21, 2022
Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN)Nathaniel R Wilson, Naveen PemmarajuPageof 41